Rationale and design of the self-management of anticoagulation in patients with non-valvular atrial fibrillation (SMAAF) study;Hintergrund und prufplan der studie zum selbstmanagement der antikoagulation bei patienten mit nichtvalvularem vorhofflimmern (SMAAF- studie)

Zeitschrift fur Kardiologie

Volumn 89, Issue 4, 2000, Pages 284-288

  Voller H ^a   Glatz, J ^b   Taborski, U ^c   Bernardo, A ^d   Dovifat, C ^a   Burkard, G ^e   Heidinger, K ^c  

^a Klinik am See   (Germany)

^b Klinik Lazariterhof   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d Klinik Gais   (Switzerland)

^e ANFOMED ^*  (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Self management

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION; SOCIAL ASPECT; SOCIOECONOMICS; THROMBOEMBOLISM; ADULT; AGED; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT CARE; PROSPECTIVE STUDY; SELF CARE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PATIENT CARE TEAM; PROSPECTIVE STUDIES; SELF CARE; TREATMENT OUTCOME;

EID: 0034169877     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920050486     Document Type: Article

References (24)

1. 1. Albers GW (1994) Atrial fibrillation and stroke. Arch Intern Med 154:1443-1448
2. 2. Ansell J, Holden A, Knapic N (1989) Patient self-management of oral anticoagulation guided by capillary blood prothrombin times. Arch Intern Med 149: 2509-2511
3. 3. Bernardo A (1996) Post-conference session: Experience with patient self-management of oral anticoagulation. J Thromb Thrombolysis 2:321-325
4. 4. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C (1991 ) Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 18:349-355
5. 5. EAFT Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
6. 6. Ezekowitz M, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation (SPINAF). N Engl J Med 12:1406-1412
7. 7. Feinberg WM, Blackshear JL, Laupacis A, et al (1995) Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 155:469
8. 8. Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage: Facts and hypotheses. Stroke 26: 1471-1477
9. 9. Petersen P, Kastrup J, Helvveg-Larsen S, Boysen G, Godtfredsen J (1990) Rise factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Arch Intern Med 150: 819-821
10. 10. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69: 236-239
11. 11. SAS/STAT® (1990) User's Guide, Version 6, Fourth Edition, Volume 2, SAS Institute Inc., Cary, NC
12. 12. Sawicki PT on behalf of the SPOG-Study group (1999) A structured teaching and self-management program for patients receiving oral anticoagulation. JAMA 281: 145-150
13. 13. Singer DE (1998) Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. Am J Cardiol 81 (5A):35C-40C
14. 14. Stafford RS, Singer DE (1998) Recent national patterns of warfarin use in atrial fibrillation. Circulation 97:1231-1233
15. 15. Stroke Prevention in Atrial Fibrillation Investigators (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 348:633-638
16. 16. Stroke Prevention in Atrial Fibrillation Investigators (1991) Stroke prevention in atrial fibrillation (SPAF) study. Final results. Circulation 84:527-539
17. 17. Taborski U, Heidinger K, Jovin I, Mülier-Berghaus G (1997) Pass study (patient's safety by self-management of oral anticoagulation): first results. Annals of Hematology. Suppl II, 74: A 132 (Abstr)
18. 18. Taborski U, Wittstamm FJ, Bernardo A (1999) Cost-effectiveness of self-managed anticoagulant therapy in germany. Sem Thromb and Hemost 25:103-107
19. 19. The Boston area anticoagulation trial for atrial fibrillation investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic trial fibrillation (BAATAF). N Engl J Med 323: 1505-1511
20. 20. The European atrial fibrillation trial study group (1995) Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333:5-10
21. 21. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76:12-16
22. 22. Van Swieten JC, Kondstaal PJ, Visser MC, Schonten HJA, van Gijn J (1988) Interobserver agreement in stroke patients. Stroke 19:604-607
23. 23. Whittle J, Wickenheiser L, Venditti L (1997) Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 157:441-445
24. 24. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22:983-988